Safety and efficacy of Vonoprazan-based triple therapy against Helicobacter pylori infection: A single-center experience with 1118 patients.
Journal Information
Full Title: Therap Adv Gastroenterol
Abbreviation: Therap Adv Gastroenterol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Gastroenterology & Hepatology
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Conflict of interest statement: The Division of Gastroenterology at Nagasaki University Hospital, Japan (Yuko Akazawa and Kazuhiko Nakao) received funding of 500,000 Yen from Takeda Pharmaceutical Company Limited in 2015. However, this study was not supported by this funding. Fukuda Yutaka Surgery Clinic (Daisuke Fukuda and Yutaka Fukuda) received fees from Takeda Pharmaceutical Company during clinical trial of reflux esophagitis and gastric ulcers using vonoprazan. However, this study was not supported by this funding."
"Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025